Back to GSKView full pipeline
Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
Drug Information
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Regulatory Approvals
EMA8/22/2007
Atriance
Nelarabine is indicated for the treatment of patients with T-cell acute lymphoblastic leukaemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens. Due to the small patient populations in these disease settings, the information to support these indications is based on limited data.
View on EMADrug Science
Mechanism of action & safety profile
Related Pipeline
FluoridePhase 3
Dental Caries
Combined Hepatitis A and B vaccinePhase 3
Hepatitis B
62.5/25mcgPhase 3
Pulmonary Disease, Chronic Obstructive
Losmapimod 7.5 mg twice dailyPhase 3
Acute Coronary Syndrome
GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix)Phase 3
Infections, Meningococcal
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts